Association between FGFR2b Positivity and Survival Outcomes of Patients with Gastric Cancer Treated with First-Line Nivolumab Plus Chemotherapy
FGFR2b expression exhibits substantial intratumoral heterogeneity in gastric cancer and may be linked to favorable outcomes in patients undergoing first-line ICI plus chemotherapy. Therefore, future studies should validate this finding, along with mechanistic investigations.
Authors
- Hyungeun Lee
- Jaewon Hyung (ORCID: https://orcid.org/0000-0002-0680-4486)
- H.S. Lee (ORCID: https://orcid.org/0009-0001-2981-3692)
- Hyung‐Don Kim (ORCID: https://orcid.org/0000-0001-9959-0642)
- Min‐Hee Ryu (ORCID: https://orcid.org/0000-0002-1033-1263)
- Young Soo Park
- Jungeun Ma
- Meesun Moon
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-11-24
- DOI
- https://doi.org/10.4143/crt.2025.598
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Taiho Pharmaceutical
- Astellas Pharma
- Ono Pharmaceutical
- Genentech
- Daiichi Sankyo Europe